Cited 0 times in

진행성 간암에서 전신 요법

Other Titles
 Systemic Therapy in Advanced Hepatocellular Carcinoma 
Authors
 최혜진 
Citation
 Journal of the Korean Liver Cancer Study Group (대한간암연구회지), Vol.11(1) : 33-39, 2011 
Journal Title
Journal of the Korean Liver Cancer Study Group(대한간암연구회지)
ISSN
 1598-6314 
Issue Date
2011
Keywords
Hepatocellular carcinoma ; Chemotherapy ; Sorafenib ; Molecular targeted agent
Abstract
Understanding the mechanism of hepatocarcinogenesis has provided the opportunity to evaluate the efficacy of molecularly targeted agents in HCC. Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic, and Raf kinase inhibitory effects, and it is the first new agent to consistently prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). The success of sorafenib is a milestone for systemic therapy of HCC, shifting the paradigm of systemic treatment to molecular targeted agents. Many novel agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are under clinical development. This review attempts to summarize the current status and future perspectives of systemic therapy in HCC.
Full Text
http://kiss.kstudy.com/journal/thesis_name.asp?tname=kiss2002&key=3009645
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/95081
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links